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Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by a combination
of autonomic failure, cerebellar ataxia, and parkinsonism. Laryngeal stridor is an additional feature
for MSA diagnosis, showing a high diagnostic positive predictive value, and its early occurrence
might contribute to shorten survival. A consensus definition of stridor in MSA is lacking, and
disagreement persists about its diagnosis, prognosis, and treatment. An International Consensus
Conference among experts with methodological support was convened in Bologna in 2017 to
define stridor in MSA and to reach consensus statements for the diagnosis, prognosis, and
treatment. Stridor was defined as a strained, high-pitched, harsh respiratory sound, mainly in-
spiratory, occurring only during sleep or during both sleep and wakefulness, and caused by
laryngeal dysfunction leading to narrowing of the rima glottidis. According to the consensus,
stridor may be recognized clinically by the physician if present at the time of examination, with the
help of a witness, or by listening to an audio recording. Laryngoscopy is suggested to exclude
mechanical lesions or functional vocal cord abnormalities related to different neurologic con-
ditions. If the suspicion of stridor needs confirmation, drug-induced sleep endoscopy or video
polysomnography may be useful. The impact of stridor on survival and quality of life remains
uncertain. Continuous positive airway pressure and tracheostomy are both suggested as symp-
tomatic treatment of stridor, but whether they improve survival is uncertain. Several research gaps
emerged involving diagnosis, prognosis, and treatment. Unmet needs for research were identified.
*These authors contribute equally to the manuscript.
From the IRCCS (P.C., G.C.-B., G.G., F.P., L.V.), Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Dipartimento di Scienze Biomediche e Neuromotorie (P.C., G.C.-B., G.G.,
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Multiple system atrophy (MSA) is a progressive neurodegen-
erative disorder characterized by a variable combination of
autonomic failure, cerebellar ataxia, and parkinsonian features,
typically poorly responsive to levodopa. The diagnostic criteria
define 3 degrees of certainty for diagnosis, possible, probable,
and definite, and 2 phenotypes, parkinsonian (MSA-P) and
cerebellar (MSA-C), according to the predominant feature at
the time of evaluation.1,2 Causes of death in MSA commonly
include bronchopneumonia, urosepsis, or sudden death that
often occurs during sleep.2
Several sleep-related breathing disorders, including stridor and
central and obstructive sleep apneas, frequently occur in
MSA.3,4 Stridor has been included in the diagnostic criteria as
additional feature for the diagnosis of possible MSA, showing
a high diagnostic positive predictive value.5–7 A recent study has
suggested that early stridor onset is an independent risk factor
for shorter survival8; however, its prognostic role remains
controversial.9–11 This may be a consequence of the distinct
design, population characteristics, and MSA diagnostic cer-
tainty (clinical vs autopsy based) across studies. Furthermore,
the lack of a universal definition for stridor and a gold standard
for its diagnostic assessment may explain result heterogeneity.
Two main options have been suggested for treating stridor:
tracheostomy or continuous positive airway pressure (CPAP).5
Tracheostomy is currently preferred in the advanced disease
stage for severe stridor and in case of stridor during wakefulness
with immobile vocal cords on laryngoscopy.5 CPAP as a non-
invasive therapy can be used for mild and moderate intensity
stridor occurring during sleep and related obstructive apneas.
However, guidelines for stridor management are lacking, and
only a few studies have assessed the role of stridor treatment on
survival.8,12–14 The “Istituto di Ricovero e Cura a Carattere
Scientifico delle Scienze Neurologiche di Bologna” (IRCCS-
ISNB) promoted an international consensus conference among
experts in the field with methodological support, convened in
Bologna, Italy, on October 6 and 7, 2017. The aims of the
conference were to (1) determine criteria for the diagnosis of
stridor and consequently define stridor in MSA, (2) define the
prognostic value of stridor on MSA survival, (3) suggest ther-
apeutic options for stridor, and (4) provide statements for future
research after systematically reviewing evidence and identifying
unmet needs for clinical practice and research gray zones.
Methods
The method was inspired by the US National Institutes of
Health Consensus Development Program15 and adapted
from the Methodological Handbook of the Italian National
Guideline System.16 The consensus conference method is
recommended for addressing important clinical questions
in the face of limited good quality evidence. The main
outcome, a consensus statement, represents the collective
opinions of an expert panel, derived from systematic re-
view and discussion of available evidence.17 The organizer
of the Bologna Consensus Conference was the IRCCS-
ISNB, Italy. Planning and execution of the project was
performed in 4 phases: (1) assignment, (2) scoping, (3)
assessment, and (4) the consensus conference itself. All
activities, from conception to realization, were completed
between February and October 2017. During the same
period, a parallel project on dysphagia in patients with
MSA was performed.
In (1) the assignment phase, the entities and their roles were
defined, and participants were nominated and invited. Four
entities were appointed: (1) the Scientific Committee (6
members) planned and organized the whole project, nomi-
nated the Consensus Development Panel and Workgroup
members, and chose the questions to be answered by the
Workgroup; (2) the Technical Committee (2 members)
established methods and rules of the Consensus Conference,
assisted with defining questions, and performed the sys-
tematic review with evidence mapping; (3) 1 Workgroup of
experts (8 members) focused on stridor, synthesized and
integrated information from the systematic review before the
consensus conference, provided shared answers to the pro-
posed questions, and presented their findings during the
Consensus Conference, including research gaps and a pro-
posal for future research; and (4) the Consensus De-
velopment Panel (8 members) chaired the Consensus
Conference, established presentation procedures, and pro-
vided final statements.
In (2) the scoping phase, the scope and the protocol for the
systematic review (registered on PROSPERO database,
PROSPERO 2018 CRD42018079084)18 and the protocol
for the conference were defined. The Scientific Committee
identified the topics and together with the Technical
Committee formulated the questions to be addressed. The
questions were framed according to the Problem/Patient/
Population, Intervention/Indicator, Comparison, Out-
come model.19
In (3) the assessment phase, the Technical Committee per-
formed a systematic review with evidence mapping to assess the
state of knowledge on stridor in MSA. The systematic review
Glossary
CPAP = continuous positive airway pressure; DISE = drug-induced sleep endoscopy; IRCCS-ISNB = Istituto di Ricovero e
Cura a Carattere Scientifico delle Scienze Neurologiche di Bologna;MSA =multiple system atrophy;MSA-C =MSA-cerebellar;
MSA-P = MSA-parkinsonian; VPSG = video polysomnography.
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was performed following accepted criteria for the good conduct
and reporting of systematic reviews18 and reported according to
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines.20 The descriptive map of available research
evidence was performed by adapting the methodology reported
by the Global Evidence Mapping Initiative,21 which involved
detailed coding of included studies and in-depth syntheses of
the available research. Studies eligible for inclusion were pub-
lished studies of any kind of design reporting original data on
subjects with MSA having stridor during sleep, dealing with
diagnosis, prognosis, and/or treatment. Studies published in
abstract form, narrative review, or concept papers were ex-
cluded. Published studies were identified from the National
Library of Medicine’s MEDLINE database, Elsevier’s EMBASE
database, and the Cochrane Central Register of Controlled
Trials by means of specific search strategies, using a combina-
tion of exploded MeSH terms and free text combing the con-
cepts of stridor in sleep andMSA (see protocol on PROSPERO
for details). Reference lists of identified articles were reviewed to
find additional references. All abstracts or full articles without
electronic abstracts were reviewed independently by 2 reviewers
to identify potentially relevant studies. Each study was classified
according to various descriptors, including topic domain, sam-
ple size, design, presence of diagnostic criteria of the stridor, and
level of evidence according to the Classification of Evidence
Schemes of the Clinical Practice Guideline Process Manual of
the American Academy of Neurology (2011).22 Briefly, each
study was graded according to its risk of bias from Class I
(highest quality) to Class IV (lowest quality). Risk of bias was
judged by assessing specific quality elements (i.e., study design,
patient spectrum, data collection, and masking) for each clinical
topic (diagnostic accuracy, prognostic accuracy, and therapeu-
tic). Disagreement between the 2 reviewers was resolved by
discussion.
The Technical Committee then sent to the Workgroup
experts a detailed summary of the systematic review with
evidence mapping, the questions, and the abstracts of the
most prominent studies, classified by topic and quality. The
workgroup produced draft answers to be discussed during the
Consensus Conference.
The Consensus Conference (4) was held over 2 days (Oc-
tober 6 and 7, 2017) in Bologna. On the first day, the Con-
sensus Development Panel established the rules for the open
discussion meetings, appraised the state of knowledge on
stridor in MSA and the preliminary answers provided by
experts, and proposed future strategies for the publication of
the consensus statements. During a contemporaneous closed
meeting, the experts independently discussed and reached
final answers to the questions assigned to them. Finally, an
open discussion was held in which experts presented their
findings and all participants debated openly to reach con-
sensus regarding each topic and the need for further research.
On the second day, the Consensus Development Panel
drafted a summary of the findings in a closed session. The
chairperson then reported the findings in an open session that
included the consensus conference participants and other
members of the scientific community and officials from the
organizing institution. Finally, experts gave a presentation on
needs for future research.
Results
Systematic review with evidence mapping
The literature search was performed in July 2017 and retrieved
212 citations after duplicate removal (figure). Each retrieved
article was screened to assess potential relevance, and 53 were
reviewed from the full text for inclusion. A total of 42 studies
finally met the prespecified inclusion criteria, and 34 were used
as basis for the statements. The majority of studies on diagnosis
and treatment were of Class IV quality; those on prognosis of
Class III (tables 1–4). Most studies on diagnosis and treatment
included fewer than 10 patients and were case series or case
reports as design. The cohort design was used in themajority of
prognosis studies.
Diagnosis of stridor
Stridor is a respiratory disturbance that in MSA typically occurs
during sleep and might develop at any time point in the disease
process. According to clinical and clinicopathologic studies,
stridor prevalence inMSA ranges from12% to 42%8–12,23–25 and
is similar inMSA-C andMSA-P.8,9,11,12 In 2 studies, 4%–5.2% of
patients presented stridor as an initial manifestation of MSA.8,26
The clinical diagnosis of stridor remains challenging. The
presence of a nighttime witness is typically necessary to suspect
stridor because patients may be unaware of it. A high-pitched
sound or heavy snoring are the symptoms frequently reported
in patients who eventually turn out to have stridor, illustrating
the problem of the differential diagnosis with snoring and ob-
structive sleep apnea syndrome, which are 2 other frequent
sleep-related breathing disorders in MSA.3,4,10,24,27–29
The term “peculiar snoring” was initially used to describe the
distinctive noise occurring inMSA due to vibration of the vocal
folds in inspiration, with a fundamental acoustic frequency of
260–330 Hz, different from that of ordinary soft palate snor-
ing.30 Subsequently, only a single study has analyzed the
acoustic features of stridor in 22 patients withMSA bymeans of
the Multi-Dimensional Voice Program.31 This study showed
that stridor can be decomposed into rhythmic and semi-
rhythmic waveforms. In both cases, it comprises formats and
harmonics, whose presence suggests an origin in the vocal
cords. In contrast, the sound analysis of snoring that was
available for 18 of these patients revealed an irregular-shaped
sound with no formats and harmonics.
Studies with video polysomnography (VPSG), which include
audio recording and concurrent evaluation of vocal cord
motion by fiberoptic laryngoscopy, showed that the high-
pitched sound identified as stridor in patients with MSA was
associated with impaired vocal cord abduction, paradoxical
adduction, or both during inspiration and expiration, leading
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to narrowing of the rima glottidis. This indicates that in-
spiratory vibration of the narrowed vocal cord folds causes
stridor.32–38
In 1 VPSG study exploring breathing activity and EMG ac-
tivity of the respiratory muscles, stridor was accompanied by
overactivation of intercostalis and diaphragmatic muscles. In
this study, the observation of tonic and subcontinuous muscle
recruitment with phasing out of thoracic as opposed to ab-
dominal respiratory traces with paradoxical inward move-
ments of the abdominal wall during inspiration was suggestive
of paradoxical breathing.37
Further VPSG studies showed that other sleep-related re-
spiratory disturbances such as snoring, central and obstructive
sleep apneas, and breathing rate abnormalities (i.e., a patho-
logic breathing rate increase during non-REM and sleep) may
occur in patients with MSA with and without
stridor.12,24,33,37–39
Laryngoscopy during wakefulness in patients with MSA with
stridor, performed to exclude secondary causes or functional
vocal cord abnormalities related to other neurologic con-
ditions, can reveal bilateral or unilateral impairment of vocal
cord abduction of varying severity or normal vocal cord
motility.27,29,32,33,35,36,39–44 Conversely, impairment of vocal
cord motility during wakefulness was also observed in patients
with MSA without stridor during sleep.27
Studies with drug-induced sleep endoscopy (DISE) dem-
onstrated impaired abduction or paradoxical adduction
of the vocal cords in patients with MSA with stridor
who had normal vocal cord motility on awake
laryngoscopy.32,33,35–37,41–44
Finally, a few studies have performed EMG of laryngeal
muscles during wakefulness and drug-induced sleep.
Patients with MSA with stridor could present normal EMG
activity of adductor and abductor laryngeal muscles during
quiet breathing and inspiration. Alternatively, they could
show a neurogenic pattern of muscle unit action potential
analysis of these muscles associated with tonic activity of
adductor muscles during quiet breathing and paradoxical
activity during inspiration. During drug-induced sleep, the
main patterns were persistent tonic activity or paradoxical
activation of laryngeal adductor muscles during
inspiration.35–38,44–46
Figure Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram
Process and result of the systematic search
for studies on stridor in multiple system
atrophy.
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Statements on the diagnosis of stridor
Clinical features suggesting the presence of stridor
Statements are based on core literature consisting of Class IV
level studies10,12,24,31 and expert opinion.
c Stridor is suspected when a high-pitched breathing sound
is emitted by the patient during sleep or while awake, or
when reported by caregivers.
c Stridor is probably underrecognized because patients and
caregivers may be unaware of its presence, especially
when it occurs at night.
c Recognition could be possible by the patient or
caregiver after imitation of stridor by the physician
(see supplementary sound track file, links.lww.com/
WNL/A973).
Home audio recording to support the diagnosis of stridor
Statement is based on expert opinion because literature on the
use of home audio recording to support the diagnosis of
stridor (differential diagnosis of stridor from snoring) is
lacking.
c Patients and caregivers should be encouraged to audio
record episodes of suspected stridor.
VPSG to support the diagnosis of stridor
Statements are based on core literature consisting of Class IV
level studies10,12,24,31,33,37–39 and expert opinion.
c VPSG including audio is not necessary if the physician
has already diagnosed stridor.
c VPSG including audio may demonstrate stridor and its
inspiratory nature.
c VPSG can characterize other sleep sounds.
Laryngoscopy for assessing stridor
Statements are based on core literature consisting of Class
IV level studies27,29,32–37,39–44 and expert opinion.
c Laryngoscopy can exclude mechanical lesions (e.g.,
masses and scars) or functional vocal cord abnormalities
related to different neurologic conditions (central or
peripheral disorders).
c Laryngoscopy may reveal vocal cord motility impairment
in patients with MSA with stridor.
c If awake laryngoscopy is normal, DISEmight be considered
if the suspicion of sleep-related stridor needs confirmation.
Other investigations for assessing stridor
Statements are based on core literature consisting of Class IV
level studies35–38,44–46 and expert opinion.
c There is no evidence that other investigations are useful.
c EMG of the laryngeal muscles may show denervation or
abnormal hyperactivity.
Conclusion on diagnostic criteria for stridor and definition of
stridor in MSA
c Stridor in MSA is a strained, high-pitched, harsh
respiratory sound, mainly inspiratory, caused by laryngeal
dysfunction leading to narrowing of the rima glottidis. It
may occur only during sleep or it may be present both
during sleep and wakefulness.
c Stridor may be recognized clinically if present at the time
of neurologic examination, with the help of a witness, or
by listening to an audio recording.
c Laryngoscopy is suggested to exclude mechanical lesions
(e.g., masses and scars) or functional vocal cord
abnormalities related to different neurologic conditions
(central or peripheral disorders).
Table 1 Descriptive features of eligible studies on stridor in MSA
All
studies














Topic N N N N N N N
Diagnosis 24 <10 pts = 14 studies — 2 5 10 7 All studies
Class IV
10–19 pts = 7 studies
20–50 pts = 3 studies
Prognosis 11 <50 pts = 6 studies 10 — — 1 — 2 Class II
50–99 pts = 3 studies 8 Class III
>100 pts = 2 studies 1 Class IV
Treatment 25 <10 pts = 12 studies 8 — — 10 7 3 Class III
10–19 pts = 6 studies 22 Class IV
20–50 pts = 7 studies
Abbreviation: MSA = multiple system atrophy; pts = patients.
Each study is graded according to its risk of bias from Class I to Class IV (with I being highest and IV lowest quality).
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c If awake laryngoscopy is normal and the suspicion of
sleep-related stridor needs confirmation, the following
additional evaluations might be considered: (1) DISE
and (2) VPSG to document the inspiratory nature of the
sound, the presence of expiratory intercostalis activation,
or the presence of associated sleep breathing disorders.
Table 2 Studies that form the basis of the statements on diagnosis with their level of evidence
First










17 (11 with stridor) + 40
normal controls















12 (9 with stridor) +
controls





18 Endoscopy; polysomnography No IV
Iranzo, 2004 Cross-
sectional
40 (14 with stridor) Polysomnography No IV
Isono, 2001 Case
series





7 Awake and sleep-induced laryngoscopy No IV
Koo, 2016 Cross-
sectional
22 Acoustic analysis Yes IV
Merlo, 2002 Case
series

















8 Acoustic analysis of snoring, polysomnography,





























19 (8 with stridor) Polysomnography; intraesophageal pressure













12 Fiberoptic laryngoscopy No IV
Each study was classified according to various descriptors, including topic domain, sample size, design, presence of diagnostic criteria of the syndrome, and
level of evidence according to the Classification of Evidence Schemes of the Clinical PracticeGuideline ProcessManual of the American Academy ofNeurology
(2011). Each study was graded according to its risk of bias from Class I to Class IV (with I highest quality and IV lowest quality). Risk of bias was judged by
assessing specific quality elements (i.e., study design, patient spectrum, data collection, and masking) for each clinical topic (diagnostic accuracy, prognostic
accuracy, and treatment).
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Prognostic value of stridor
Retrospective cohort studies have reported conflicting results
on the prognostic value of stridor.47 Seven studies did not find
an association between the presence of stridor during the
disease course and shortened survival.8,9,11,14,48–50 In most of
these studies, stridor was clinically suspected without in-
strumental confirmation. In contrast, 1 study showed shorter
survival in patients with MSA with stridor after VPSG re-
cording, but not from disease onset.10 Finally, the largest
study with VPSG found that early onset of stridor (within 3
years from motor or autonomic symptom onset) was an in-
dependent predictor of shorter survival.8 Based on an analysis
with the Multi-Dimensional Voice Program, 1 study reported
that acoustic features of stridor may affect survival in MSA.31
Statements on the prognostic value of stridor
Effect of stridor on survival
Statements regarding the effect of stridor on survival in MSA
are based on core literature consisting of Class II/III level
studies,8–11,14,31,48–50 a systematic review,47 and expert opinion.
c Whether stridor affects survival is uncertain.
c Stridor within 3 years of motor or autonomic symptom
onset may shorten survival. However, identification of
stridor onset may be difficult.
c Whether specific features of stridor affect survival remains
to be determined.
c Stridor during wakefulness is widely considered to reflect
a more advanced stage of the disease than stridor
occurring during sleep.
Effect of stridor on well-being or health-related quality of life
Literature on the effect of stridor on well-being or health-related
quality of life is lacking. Statements are based on expert opinion.
c Stridor can be distressing for patients and caregivers.
c The impact on health-related quality of life remains to be
determined.
Treatment of stridor
Four retrospective studies reported that the treatment of
stridor improves survival.8,12–14 Stridor treatment mainly
comprised CPAP or tracheostomy.10,27,29,32,33,35,39,51,52 In 3
studies (<15 patients), CPAP initially eliminated stridor in
almost all patients,12,13,51 but the long-term symptomatic ef-
fect remains unknown.
Three studies reported survival in patients with MSA treated
with CPAP. In 1 small study, CPAP had no effect on sur-
vival.10 In another prospective cohort study, patients with
MSA with stridor receiving CPAP (n = 13) had similar me-
dian survival compared with a group of patients with MSA
without stridor (n = 26).12 Sudden death was reported in 2 of
13 patients following CPAP initiation.13
Classic tracheostomy is usually the surgical procedure of
choice for stridor. This involves the positioning of a fenes-
trated cannula, maintained closed during the day to allow
phonation.53 Alternative techniques such as skin-lined tra-
cheostomy have recently been proposed for the treatment of
severe stridor in MSA.54 Skin-lined tracheostomy offers sev-
eral advantages, such as a greater opening of the stoma, higher
stability over time, less risk of granulation tissue, and re-
versibility. In addition, it does not require a cannula during the
night, and the stoma is easy to plug during the day.
Three studies focused on the role of tracheostomy on survival.
In the largest retrospective study (n = 42 with stridor),
patients treated with tracheostomy had longer overall disease
Table 3 Studies that form the basis of the statements on prognosis with their level of evidence
First author, y Design No. of patients Level of evidence
Coon, 2015 Cohort 685 (176 with stridor) II
Giannini, 2016 Cohort 136 (42 with stridor) III
Glasmacher, 2017 Systematic review 6 studies Not available
Koo, 2016 Cohort 22 III
Krim, 2007 Cohort 86 (17 with stridor) II
Lalich, 2014 Cohort 38 (25 with stridor) III
Silber, 2000 Cohort 42 (30 with follow-up data, 11 with stridor) III
Starhof, 2016 Cohort 99 (44 with stridor) II
Tada, 2007 Cohort 49 (18 with stridor) III
Yamaguchi, 2003 Cohort 83 (33 with stridor) III
Each study was classified according to various descriptors, including topic domain, sample size, design, presence of diagnostic criteria of the syndrome, and
level of evidence according to the Classification of Evidence Schemes of the Clinical Practice Guideline ProcessManual of the American Academyof Neurology
(2011). Each study was graded according to its risk of bias from Class I to Class IV (with I highest quality and IV lowest quality). Risk of bias was judged by
assessing specific quality elements (i.e., study design, patient spectrum, data collection, and masking) for each clinical topic (diagnostic accuracy, prognostic
accuracy, and treatment).
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duration, longer disease duration after stridor onset, and
longer disease duration after treatment compared with those
treated with CPAP.8 Another study showed that tracheos-
tomy may reduce the risk of death and of sudden death in
patients with MSA with stridor.11 One study reported that 2
of the 4 patients with tracheostomy died 1 year after the
sleep evaluation, whereas the other 2 were alive 1.9 and 7
years later.10
Single case reports have described the use of posterior cordotomy
and arytenoidectomy,28,43,44,55 and botulinum toxin relieved
dystonic stridor in 3 of 4 patients 1 month after inoculation.45
Statements on the treatment of stridor
Treatment for symptomatic control of stridor
Statements are based on core literature consisting of Class III/
IV level studies8,10–14,27,29,32,33,35,39,49,51,52 and expert opinion.
c Ventilation during sleep (CPAP) can be useful in the
symptomatic control of stridor.
c Consider ventilation during sleep (CPAP) as a first-line
symptomatic therapy.
c Tracheostomy bypasses upper airway obstruction at
laryngeal level and relieves distressing stridor. Tracheos-
tomy is effective in the symptomatic control of stridor.
c Persistent and severe stridor may require tracheostomy.
CPAP for improving survival of patients with stridor
Statement is based on core literature consisting of Class III/IV
level studies.8,10,12,13
c Whether CPAP improves survival in patients with MSA
with stridor is uncertain.
Tracheostomy for improving survival of patients with stridor
Statement is based on core literature consisting of Class III/IV
level studies.8,10,11
c Tracheostomy might improve survival in patients with
stridor.
Table 4 Studies that form the basis of the statements on therapy with their level of evidence
First author, y Design No. of patients Treatment Level of evidence
Blumin, 2002 Case series 7 CPAP: bilevel positive airway pressure; tracheostomy IV
Chitose, 2012 Case report 1 CPAP; laser arytenoidectomy IV
Ghorayeb, 2005 Case series 22 (15 with stridor) CPAP IV
Giannini, 2016 Cohort 136 (42 with stridor; 31 treated) CPAP (19 pts); tracheostomy (12 pts) III
Harcourt, 1996 Case series 18 CPAP (2 pts); tracheostomy (2 pts); arytenoidectomy (3 pts) IV
Iranzo, 2000 Cohort 20 (5 with stridor) CPAP IV
Iranzo, 2004 Cohort 14 (with stridor) CPAP (13 pts) IV
Isono, 2001 Case series 10 CPAP on laryngeal resistance and muscle activity (6 pts) IV
Isozaki, 1996 Case series 7 Tracheostomy IV
Jin, 2007 Case series 18 Tracheostomy (7 pts) IV
Kneisley, 1990 Case report 1 Arytenopexy; vocal cord pinning IV
Lalich, 2014 Cohort 1 CPAP IV
Mahmud, 2015 Case report 1 Laser arytenoidectomy and posterior cordotomy IV
Merlo, 2002 Case series 7 Botulinum toxin (4 pts) IV
Sadaoka, 1996 Case series 8 Tracheostomy IV
Silber, 2000 Cohort 42 (30 with follow-up data) CPAP (5 pts); tracheostomy (4 pts) IV
Stomeo, 2016 Case report 1 Subtotal arytenoidectomy IV
Tada, 2007 Cohort 18 (with stridor) Tracheotomy (12 pts) III
Williams, 1979 Case series 12 Tracheostomy (4 pts) IV
Yamaguchi, 2003 Cohort 33 (with stridor; 15 treated) CPAP; tracheostomy; laryngectomy III
Abbreviation: CPAP = continuous positive airway pressure; pts = patients.
Each study was classified according to various descriptors, including topic domain, sample size, design, presence of diagnostic criteria of the syndrome, and level of
evidence according to the Classification of Evidence Schemes of the Clinical Practice Guideline Process Manual of the American Academy of Neurology (2011). Each
study was graded according to its risk of bias fromClass I to Class IV (with I highest quality and IV lowest quality). Risk of bias was judged by assessing specific quality
elements (i.e., study design, patient spectrum, data collection, and masking) for each clinical topic (diagnostic accuracy, prognostic accuracy, and treatment).
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Other treatment options for stridor
Statement is based on core literature consisting of Class IV
level studies including case reports.28,43–45,55
c There is insufficient evidence for minimally invasive
procedures and botulinum toxin injections for the
symptomatic treatment of stridor.
Research needs
The present Consensus Conference represents the first effort
to systematically revise the literature and to provide state-
ments on stridor, a specific feature of MSA, that could affect
the disease course. However, despite the importance of this
topic, the majority of studies available in the literature were of
Class III–IV quality, leading also to statements based on ex-
pert opinions. Furthermore, several research gaps emerged
during the consensus meeting concerning diagnosis, prog-
nosis, and treatment for stridor.
One main challenge is the diagnosis of stridor. Whether the
imitation of stridor by the physician during follow-up visits is
sufficient to correctly and earlier identify stridor or whether other
tools, such as specific questionnaires or a home audio recording,
may improve diagnostic accuracy is unknown. This point could
be of crucial importance if the negative prognostic role of early
stridor onset is confirmed. It has also to be established when the
use of VPSG is necessary for the diagnosis of stridor. For these
reasons, a questionnaire for detecting stridor should be de-
veloped and its diagnostic accuracy be compared with VPSG in
a multicenter prospective study. Similarly, the diagnostic accu-
racy of sound imitation by the physician or home audio re-
cording should be evaluated. A smartphone application could be
developed to automatically recognize the stridor sound. Finally,
the place of DISE for early stridor detection requires further
investigation, and the method to measure the progression of
stridor over time should be standardized.
The relationship between stridor and other breathing disorders
(i.e., central apneas and breathing rate abnormalities) and their
respective contributions to disease prognosis and survival should
be determined through a multicenter prospective study. VPSG
should be used to determine stridor and breathing disorders in
this study.Moreover, further studies could contribute to elucidate
the role on survival of specific characteristic obtained from awake
laryngoscopy, DISE, laryngeal EMG (denervation/muscle hy-
peractivity), and acoustic recordings. In addition, the contribu-
tion of stridor to patients and caregiver quality of life is unknown.
To guide the physician for the treatment of stridor, randomized
controlled trials comparing the efficacy of CPAP and trache-
ostomy for different degrees of stridor are warranted. Studies
using laryngoscopy and/or laryngeal EMG should be conducted
to identify specific characteristics that may predict treatment
tolerance and response. Moreover, the usefulness of CPAP for
severe stridor, as well as technical aspects including titration,
patient compliance, and the timing of follow-up need to be
determined. Finally, the usefulness of bilevel PAP should be
comparedwithCPAP. Similarly to CPAP, interventional studies
should also compare skin-lined vs conventional tracheostomy.
Literature revision and the emergence of several research gaps
on diagnosis, prognosis, and treatment for stridor rise the
need of prospective multicenter studies on large samples, and
with a randomized controlled design concerning its treat-
ment, to provide high level of evidence in the role of stridor in
MSA course.
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